Serial direct sodium removal in patients with heart failure and diuretic resistance
Veena S. Rao,Juan B. Ivey‐Miranda,Zachary L. Cox,Julieta Moreno‐Villagomez,Daniela Ramos‐Mastache,Daniel Neville,Natasha Balkcom,Jennifer L. Asher,Lavanya Bellumkonda,Tamar Bigvava,Tamaz Shaburishvili,Jozef Bartunek,F. Perry Wilson,Fredrick Finkelstein,Christopher Maulion,Jeffrey M. Turner,Jeffrey M. Testani
DOI: https://doi.org/10.1002/ejhf.3196
2024-04-02
European Journal of Heart Failure
Abstract:In patients with HF and diuretic resistance, serial direct sodium removal (DSR) therapy with loop diuretic withdrawal was feasible and safe. DSR therapy along with diuretic withdrawal was associated with substantial and persistent improvement in diuretic resistance and many prognostically important cardiorenal parameters. If replicated in randomized controlled studies, DSR may represent a novel therapy for diuretic resistance and cardiorenal syndrome. DSR, direct sodium removal; HF, heart failure; NT‐proBNP, N‐terminal pro‐ B‐type natriuretic peptide; CA‐125, carbohydrate antigen‐125; IL‐6, interleukin‐6; GDF‐15, Growth differentiation factor‐15; SAE, serious adverse event. Aims Loop diuretics may exacerbate cardiorenal syndrome (CRS) in heart failure (HF). Direct sodium removal (DSR) using the peritoneal membrane, in conjunction with complete diuretic withdrawal, may improve CRS and diuretic resistance. Methods and results Patients with HF requiring high‐dose loop diuretics were enrolled in two prospective, single‐arm studies: RED DESERT (n = 8 euvolaemic patients), and SAHARA (n = 10 hypervolaemic patients). Loop diuretics were withdrawn, and serial DSR was utilized to achieve and maintain euvolaemia. At baseline, participants required a median 240 mg (interquartile range [IQR] 200–400) oral furosemide equivalents/day, which was withdrawn in all participants during DSR (median time of DSR 4 weeks [IQR 4–6]). Diuretic response (queried by formal 40 mg intravenous furosemide challenge and 6 h urine sodium quantification) increased substantially from baseline (81 ± 37 mmol) to end of DSR (223 ± 71 mmol, p
cardiac & cardiovascular systems